TRADE POLICY | 2026-09-09

Section 232 Pharmaceutical Tariffs and the September 29, 2026 Deadline: A Compliance Guide for California Importers, Distributors, and Health Systems

What San Diego and Bay Area biopharma companies, pharmaceutical distributors, and hospital systems must do before the second-phase 100 percent tariff on branded drugs and APIs takes effect

By Anatolii Trembach, Esq. (California State Bar No. 349304; LL.M., USC Gould School of Law; admitted to the U.S. Court of International Trade), Trembach Law Firm, APC · Published

On September 29, 2026, the second and broadest phase of the Section 232 pharmaceutical tariff program takes effect, extending a 100 percent ad valorem duty on imported patented pharmaceutical products and their active pharmaceutical ingredients to companies beyond the initial group of large manufacturers, while generic pharmaceuticals and their ingredients remain excluded.

Contact Trembach Law Firm at (818) 514-7680 for a confidential consultation.

Trembach Law Firm | 27001 Agoura Road, Suite 350, Calabasas, CA 91301